# CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be

- a) a guide for reporting for authors of RCTs,
- b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the

caption):
Eysenbach G, CONSORT-EHEALTH Group
CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and
Mobile Health Interventions
J Med Internet Res 2011;13(4):e126
URL: <u>http://www.jmir.org/2011/4/e126/</u>
doi: 10.2196/jmir.1923
PMID: 22209829

🤣 joseavil@gmail.com (no compartidos) Cambiar de cuenta 🛛 🙆 Borrador guardado

\*Obligatorio

Your name \*

First Last

Avila-Tomas, JF

Primary Affiliation (short), City, Country \* University of Toronto, Toronto, Canada

SERMAS, Madrid, Spain

Your e-mail address \* abc@gmail.com

joseavil@gmail.com

Title of your manuscript \*

Provide the (draft) title of your manuscript.

Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care

Name of your App/Software/Intervention \*

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

Dejal@bot

Evaluated Version (if any)

e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

2.4

() Your answer must have a minimum of 5 characters.

Language(s) \*

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

Spanish

#### URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

https://cuidabot.es/dejalobot

URL of an image/screenshot (optional)

https://cuidabot.es/dejalobot

#### Accessibility \*

Can an enduser access the intervention presently?

- ) access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- ) app/intervention no longer accessible
- ) Otro:

Primary Medical Indication/Disease/Condition \*

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

**Tobacco Smokers** 

Primary Outcomes measured in tri
----------------------------------

comma-separated list of primary outcomes reported in the trial

Continuous abstinence rate biochemical valida

#### Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

changes in quality of life, number of contacts between the therapist or the chatbot and the patient, and total time of interaction.

#### Recommended "Dose" \*

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Otro:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months	*
O unknown / not evaluated	
0-10%	
0 11-20%	
O 21-30%	
31-40%	
41-50%	
51-60%	
61-70%	
O 71%-80%	
81-90%	
91-100%	
O Otro:	

Overall, was the app/intervention effective? *								
• yes: all primary outcomes were significantly better in intervention group vs control								
O partly: SOME primary outcomes were significantly better in intervention group vs control								
O no statistically significant difference between control and intervention								
O potentially harmful: control was significantly better than intervention in one or more outcomes								
O inconclusive: more research is needed								
O Otro:								
Article Preparation Status/Stage * At which stage in your article preparation are you currently (at the time you fill in this form)								
At which stage in your article preparation are you currently (at the time you fill in this form)								
At which stage in your article preparation are you currently (at the time you fill in this form) O not submitted yet - in early draft status								
At which stage in your article preparation are you currently (at the time you fill in this form) <ul> <li>not submitted yet - in early draft status</li> <li>not submitted yet - in late draft status, just before submission</li> </ul>								
At which stage in your article preparation are you currently (at the time you fill in this form) <ul> <li>not submitted yet - in early draft status</li> <li>not submitted yet - in late draft status, just before submission</li> <li>submitted to a journal but not reviewed yet</li> </ul>								

O Otro:

#### Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Otro:

Is this a full powered effectiveness trial or a pilot/feasibility trial? \*

) Pilot/feasibility

Fully powered

#### Manuscript tracking number \*

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

) no ms number (yet) / not (yet) submitted to / published in JMIR

Otro:	JI
0000	

otro: JMU ms#34273


#### TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *
I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")
• yes
O Otro:

#### 1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.




#### Does your paper address subitem 1a-i? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care

#### 1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").



Does your paper address subitem 1a-ii?										
Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
Effectiveness of a Conversational Chatbot (Dejal@bot) for the Adult Population to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care										
<b>1a-iii) Primary condition or target group in the title</b> Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial										
	1	2	3	4	5					
subitem not at all important	0	0	0	0	٢	essential				
Borrar selección										

#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Effectiveness of a Conversational Chatbot (Dejal@bot) for the "Adult Population" to Quit Smoking: Pragmatic, Multicenter, Controlled, Randomized Clinical Trial in Primary Care


#### 1b) ABSTRACT: Structured summary of trial design, methods, results, and

#### conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

# 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Smokers over the age of 18 years who attended on-site consultation and accepted help to quit tobacco were recruited by their doctor or nurse and randomly allocated to receive usual care (control group [CG]) or an evidence-based chatbot intervention (intervention group [IG]). The interventions in both arms were based on the 5A's (ie, Ask, Advise, Assess, Assist, and Arrange) in the US Clinical Practice Guideline, which combines behavioral and pharmacological treatments and is structured in several follow-up appointments.

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT									
Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)									
1	2	3	4	5					
0	0	0	0	۲	essential				
Borrar selección									
	nt in the al cian-assis ract what t	nt in the abstract, e.c cian-assisted" (ment ract what the main p adding it)	nt in the abstract, e.g., use phra cian-assisted" (mention numbe ract what the main paper is rep	nt in the abstract, e.g., use phrases like " cian-assisted" (mention number and exp ract what the main paper is reporting. If adding it)	nt in the abstract, e.g., use phrases like "fully autom cian-assisted" (mention number and expertise of p ract what the main paper is reporting. If this inform adding it) 1 2 3 4 5 O O O O				


#### Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Smokers over the age of 18 years who attended on-site consultation and accepted help to quit tobacco were recruited by their doctor or nurse and randomly allocated to receive usual care (control group [CG]) or an evidence-based chatbot intervention (intervention group [IG]).

# 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Receive usual care (control group [CG]) or an evidence-based chatbot intervention (intervention group [IG]).

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)




#### Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sample included 513 patients (242 in the IG and 271 in the CG), with an average age of 49.8 (SD 10.82) years and gender ratio of 59.3% (304/513) women and 40.7% (209/513) men. Of them, 232 patients (45.2%) completed the follow-up, 104/242 (42.9%) in the IG and 128/271 (47.2%) in the CG.

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Tu respuesta

#### INTRODUCTION

#### 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)



#### Does your paper address subitem 2a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Tobacco addiction is the leading cause of preventable morbidity and mortality in the world. However, only 1 in 20 cessation attempts is supervised by a health professional. The potential advantages of mobile technologies for health (mHealth) can circumvent these problems and facilitate tobacco-cessation interventions for public health systems. Given its easy scalability to large populations, chatbots are a potentially useful complement to usual treatment, with the consequent savings, whether they are integrated into a global plan for aiding smokers to quit or used alone.

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Evidence regarding the effectiveness of interventions for quitting smoking with the aid of ICTs is recent. A review by Whittaker et al [14], which included 26 clinical trials and 33,849 participants, concluded that automatized interventions with SMS text messages were effective, whether as the solely delivered intervention (relative risk [RR] 1.54, 95% CI 1.19-2.00) or in combination with other interventions (RR 1.59, 95% CI 1.09-2.33). That review was the first to incorporate 5 evidence-based, quality studies comparing the effectiveness of an app for cessation with low-intensity interventions (whether using apps or not), although the effectiveness of apps for increasing the abstinence rates in the long term was not proven (RR 1.00, 95% CI 0.66-1.52). A more recent review including 4 trials using apps reported similar results (RR 0.871, 95% CI 0.543-1.397).

At the time of this writing, several clinical trials are being conducted to assess the effectiveness of a chatbot for quitting smoking [16,17] by comparing different interventions employing ICTs.

#### 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The aim of this study was to assess the effectiveness of a chatbot, with an evidence-based design and including elements of AI and natural language processing, for helping people stop smoking compared with clinical practice in primary care.

#### **METHODS**

3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This is a pragmatic, multicenter, controlled, and randomized clinical trial. The study was conducted in 34 primary health care centers in the Community of Madrid region (Spain) and had a follow-up period of 6 months.

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial protocol was previously registered [19] and no changes were made to the methods, intervention, or comparator, except for an additional analysis by subgroups, which was not included in the initial study design.

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].



#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial protocol was previously registered [19] and no changes were made to the methods, intervention, or comparator, except for an additional analysis by subgroups, which was not included in the initial study design.

#### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients included must have smoked at least one cigarette over the previous month, accept professional help for quitting in the following month, own a smartphone in which a messaging app (Telegram) could be installed, confirm their availability to be reached for 6 months following the intervention, and provide informed written consent.

### 4a-i) Computer / Internet literacy Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified. 1 2 3 4 5

#### Does your paper address subitem 4a-i?

subitem not at all important

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


essential

Borrar selección

Computer or internet illiteracy of patients was not assessed.

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients included were smokers aged over 18 years who visited their doctor or nurse for consultation for any reason during the inclusion period

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

..and provide informed written consent. Sent as Multimedia Appendix 3 and 4

#### 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Family practitioners and nurses from the 262 health care centers in the Madrid Health Service were offered to participate.

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.



## Does your paper address subitem 4b-i? \* Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study The health care collaborators collected participants' data in a collection notebook designed ad hoc, which could be accessed from the work computer with a personal password. 4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth media], as

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)



#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Family practitioners and nurses from the 262 health care centers in the Madrid Health Service were offered to participate.

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

### 5-i) Mention names, credential, affiliations of the developers, sponsors, and

#### owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	rrar selección

#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

JFA-T, EO-E, and CM-L designed the chatbot and own the intellectual property rights. The remaining research team members (authors, developers, and sponsors) were not involved in the development of the intervention.

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Bc	orrar selección

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A pilot test was conducted prior to the beginning of the clinical trial to assess usability and to train the AI categories. The final version from the pilot study (February 2018) was implemented in the randomized controlled trial and its content was not modified at any stage.

Dejal@bot was developed based on scientific evidence by doctors with expertise in tobacco use and ICTs between 2015 and 2018 (see Multimedia Appendix 5 for screenshots of the app). Its internal structure is a script recreating the interaction between a professional and a patient that takes numerous variants as required by the patient's needs and characteristics. The chatbot is bidirectional and provides multimedia links to cessation advice (by providing access to evidence-based techniques with cognitive-behavioral, motivational, relapseprevention, and problem-solving components); information about the prescribed medication for helping to quit; and advice on how to cope with abstinence-related problems and relaxation exercises in diverse formats, such as video, graphs, games, and web links (of note, all these are similar to the resources health care workers could offer to the patients in the CG). Dejal@bot also incorporates gamification elements (knowledge and skills acquisition) with a system for scoring points and obtaining badges that grant access to specific information depending on the abstinence period and personal needs. This feedback is complemented with messages of encouragement and emphasis on the achieved goals. The intervention was described in detail in the protocol [19] and in the TIDieR (Template for Intervention Description and Replication) checklist (Multimedia Appendix 6).

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?										
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study										
The final version from the pilot study (February 2018) was implemented in the randomized controlled trial and its content was not modified at any stage										
5-iv) Quality assurance methods Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.										
	1	2	3	4	5					
subitem not at all important										
Borrar selección										
Does your paper address subitem 5-iv?										

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Data collection was monitored weekly and the collaborators were contacted in case of incongruous or incomplete information.

5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

#### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The Dejal@bot structure is simple: (1) The user writes messages in the Telegram app installed into their smartphone; (2) Telegram anonymizes this message upon receipt by assigning an identification number to the user and forwards the message to the software installed in the research team server; (3) the software processes the message; (4) our reply is sent to Telegram; and (5) Telegram forwards the response to the user.

Screenshots sent in Multimedia Appendix 5

#### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	orrar selección


#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

https://cuidabot.es/dejalobot

#### 5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).




#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A personal keyword allowed accessing the chatbot via Telegram, a widely used messaging app

# 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The intervention strategy for both arms was based on the 5A's (ie, Ask, Advise, Assess, Assist, and Arrange) in the US Clinical Practice Guideline [2]. During the recruitment phase, all patients who met the inclusion criteria were interviewed in person about their tobacco consumption and received advice to cease smoking from their doctor or nurse, who also inquired about their willingness to quit smoking. Those accepting to attempt cessation in the following month and agreed to participate in the trial were randomly assigned into the IG or the CG. Patients received a personal intervention that combined behavioral and pharmacological treatment and was structured in several follow-up visits, whether online via a chatbot or face-to-face with their assigned health care professional.

Patients in the CG received usual clinical practice that aided in their tobacco cessation process, which is based on scientific recommendations and protocols in the services portfolio of the Madrid Health System

Patients in the IG were offered an intervention with contents similar to the CG but delivered via a chatbot.No instructions or recommendations were given to the chatbot users regarding timing, frequency, or intensity of use. No further appointments were set between the professional and the patient other than the follow-up at 6 months (T1), and no additional co-interventions were provided outside the trial setting. The patient could contact the chatbot at any time and place, and decided the duration and frequency of interactions

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



#### Does your paper address subitem 5-ix?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients in the CG received usual clinical practice that aided in their tobacco cessation process, which is based on scientific recommendations and protocols in the services portfolio of the Madrid Health System.

Patients in the IG were offered an intervention with contents similar to the CG but delivered via a chatbot. No instructions or recommendations were given to the chatbot users regarding timing, frequency, or intensity of use. No further appointments were set between the professional and the patient other than the follow-up at 6 months (T1), and no additional co-interventions were provided outside the trial setting.

#### 5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Family practitioners and nurses from the 262 health care centers in the Madrid Health Service were offered to participate. The 248 health workers who volunteered as collaborators were informed of the study objectives, design, and methods, and received training about the fieldwork, handling of the data collection, and good practice in clinical research. Among them, only 161 professionals recruited participants.

Each collaborator had the objective of recruiting a minimum of 3 patients by offering participation to all smokers attending their consultation for any reason, in consecutive order, between October 1, 2018, and March 31, 2019. After checking compliance with the inclusion criteria, the patients were informed about the characteristics of the trial, and invited to participate.

Two visits were defined for patient data collection (Figure 1): baseline (T0) and at 6 months (T1). The health care collaborators collected participants' data in a collection notebook designed ad hoc, which could be accessed from the work computer with a personal password. Additionally, professionals were responsible for the clinical follow-up of patients in the control group (CG) and keeping records of it at each visit.

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).




#### Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No instructions or recommendations were given to the chatbot users regarding timing, frequency, or intensity of use. No further appointments were set between the professional and the patient other than the follow-up at 6 months (T1), and no additional co-interventions were provided outside the trial setting.

#### 5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.



#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No further appointments were set between the professional and the patient other than the follow-up at 6 months (T1), and no additional co-interventions were provided outside the trial setting.

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The primary outcome was continuous abstinence at 6 months, which was biochemically validated by CO-oximetry, involving measurement of exhaled air in parts per million (ppm), following the recommendations in the Russell Standard [20]. Therefore, the patient must declare not having smoked in the previous 6 months and have a negative CO-oximetry result (<10 ppm) to be considered a "nonsmoker."

The secondary outcomes were changes in quality of life, number of contacts between the therapist or the chatbot and the patient, and total time of interaction.

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

	1	2	3	4	5	
subitem not at all important	۲	0	0	0	0	essential
					Во	rrar selección

Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text							
Not applicable. No Online questionnaires were used in this trial.							
6a-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored							
Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	۲	essential	
					Вс	orrar selección	

### Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Information regarding contact time and number of interactions was automatically recorded in the data collection notebook (CG) or by the chatbot (IG).

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained						
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	rrar selección

Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

There was a feedback form to the chatbot users when the trial was ended.

#### 6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No changes to trial outcomes were made after the trial commenced.

#### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size Describe whether and how expected attrition was taken into account when calculating the sample size.						
	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	rrar selección

### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The sample size was calculated based on the outcomes of the FTFT-AP trial [22], a recent clinical trial that assessed the effectiveness of usual clinical practice in our health care system and reported a continuous abstinence rate of 9.6% in the CG at 6 months. Considering a 2-fold success rate compared with the later study [14], an  $\alpha$  error of 5%, and a power of 80%, the calculated sample size was 418 patients. With an estimated dropout rate of 10%, the final size was 460 smokers (230 in each arm).

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper addres	s CONSORT	subitem	7b? *
------------------------	-----------	---------	-------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Tu respuesta

## 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

## Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After providing informed consent and following the collection of baseline information, participants were randomly allocated to the intervention group (IG, chatbot) or CG (usual care) at the baseline visit (T0) via simple randomization software and without further restrictions.

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No other method was used to implement the random allocation sequence

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

## Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After providing informed consent and following the collection of baseline information, participants were randomly allocated to the intervention group (IG, chatbot) or CG (usual care) at the baseline visit (T0) via simple randomization software and without further restrictions. No other method was used to implement the random allocation sequence.

## 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

## Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Each collaborator had the objective of recruiting a minimum of 3 patients by offering participation to all smokers attending their consultation for any reason, in consecutive order, between October 1, 2018, and March 31, 2019. Via simple randomization software and without further restrictions.

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).								
1	2	3	4	5	essential			
				Borr	ar selección			
	1	1 2 C O	1 2 3 C O O	1 2 3 4 C O O O				

## Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Given the nature of the intervention, patients and professionals were aware of their treatment allocation. All analyses were performed by trial statisticians and methodologists in the Madrid Primary Care Research Unit who were blinded to the group assignment.

## 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".

	1	2	3	4	5	
subitem not at all important	0	0	0	0	0	essential

### Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Given the nature of the intervention, patients and professionals were aware of their treatment allocation.

## 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

## Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The intervention strategy for both arms was based on the 5A's (ie, Ask, Advise, Assess, Assist, and Arrange) in the US Clinical Practice Guideline.

Patients received a personal intervention that combined behavioral and pharmacological treatment and was structured in several follow-up visits, whether online via a chatbot or face-to-face with their assigned health care professional.

## 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

Does your paper address CC	ONSORT	subiter	n 12a? *					
Copy and paste relevant sections fro indicate direct quotes from your mar information not in the ms, or briefly e	nuscript), c	or elaborat	e on this it	tem by pro	viding add	litional		
Intention-to-treat analyses were performed by coding all losses to follow-up as smokers, as specified in the previously published protocol								
12a-i) Imputation techniques Imputation techniques to deal with a intervention/comparator as intended participants who did not use the app analysis (a complete case analysis is LOCF may also be problematic [4]).	ttrition / m   and attriti  ication or	nissing val ion is typic dropped c	ues: Not a cally high i out from th	ll participa n ehealth t ne trial wer	ants will us rials. Spec e treated i	cify how n the statistical		
	1	2	3	4	5			
subitem not at all important	0	0	0	0	۲	essential		

Borrar selección

## Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Intention-to-treat analyses were performed by coding all losses to follow-up as smokers, as specified in the previously published protocol.

Missing data were analyzed using the baseline-observation-carried-forward (BOCF) approach.

## 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does yo	ur paper	address	CONSORT	subitem 12b? *
---------	----------	---------	---------	----------------

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An analysis by subgroups was also conducted to account for the intensity of use with the chatbot or the contact intensity between patients and professionals.

## X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)



### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This clinical trial was approved by the Ethics Committees for Clinical Research of the Community of Madrid (December 13, 2017; approval number: 23/17) and the University Hospital 12 de Octubre (Madrid, January 30, 2018; approval number: 18/054).

## x26-ii) Outline informed consent procedures Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents. 1 2 3 4 5 subitem not at all important O O O O O essential Borrar selección


## Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After checking compliance with the inclusion criteria, the patients were informed about the characteristics of the trial, and invited to participate and read an informative document (Multimedia Appendix 3). Patients who accepted to participate provided informed consent (Multimedia Appendix 4).

## X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No safety and security procedures were taken

## RESULTS

## 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

### Does your paper address CONSORT subitem 13a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Of the 572 potentially eligible patients who had been invited to participate, 513 accepted, provided informed consent, and were thus enrolled in the trial. Measurements were obtained at the follow-up visit (T1) for 232 (45.2%) patients, 42.9% (104/242) and 47.2% (128/271) in the IG and CG, respectively, without significant intergroup differences (Figure 1).

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is *									
shown in a CONSORT flow diagram)									
Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study									
Losses and exclusion after randomization are in Fig 1 (CONSORT flow diagram)									
plotted	over time,								
1	2	3	4	5					
$\sim$	$\sim$	$\sim$	$\sim$						
0	0	0	0	igodol	essential				
				Во	rrar selección				
	iagram) m the mar suscript), o explain why omization diagram (e up plotted agagement	iagram) m the manuscript (in suscript), or elaborat explain why the item omization are in F diagram (e.g., propor up plotted over time, agagement.	iagram) m the manuscript (include que suscript), or elaborate on this in explain why the item is not app omization are in Fig 1 (CON diagram (e.g., proportion of pa up plotted over time, similar to agagement.	iagram) m the manuscript (include quotes in quo buscript), or elaborate on this item by pro explain why the item is not applicable/rel omization are in Fig 1 (CONSORT flo diagram (e.g., proportion of participants up plotted over time, similar to a survival agagement.	iagram) m the manuscript (include quotes in quotation manuscript), or elaborate on this item by providing address plain why the item is not applicable/relevant for y comization are in Fig 1 (CONSORT flow diagram) diagram (e.g., proportion of participants still loggin up plotted over time, similar to a survival curve) or elagagement. 1 2 3 4 5 0 0 0 0 0				

### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Measurements were obtained at the follow-up visit (T1) for 232 (45.2%) patients, 42.9% (104/242) and 47.2% (128/271) in the IG and CG, respectively, without significant intergroup differences (Figure 1). The analysis of dropouts also did not show significant intergroup differences (Table 2).

## 14a) Dates defining the periods of recruitment and follow-up

## Does your paper address CONSORT subitem 14a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Each collaborator had the objective of recruiting a minimum of 3 patients by offering participation to all smokers attending their consultation for any reason, in consecutive order, between October 1, 2018, and March 31, 2019.

Two visits were defined for patient data collection (Figure 1): baseline (T0) and at 6 months (T1). The health care collaborators collected participants' data in a collection notebook designed ad hoc, which could be accessed from the work computer with a personal password. Additionally, professionals were responsible for the clinical follow-up of patients in the control group (CG) and keeping records of it at each visit.

14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources"							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	۲	essential	
					Вс	orrar selección	

## Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No critical "secular events" fell into the study period.

## 14b) Why the trial ended or was stopped (early)

## Does your paper address CONSORT subitem 14b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial ended as planned in the protocol.

## 15) A table showing baseline demographic and clinical characteristics for each

#### group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

## Does your paper address CONSORT subitem 15? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Tu respuesta

## 15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	rrar selección

## Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No significant differences were found between the IG and CG at baseline in terms of sociodemographic variables or those related to their tobacco consumption (Table 1).

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

## 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

	1	2	3	4	5	
subitem not at all important	0	0	0	0	۲	essential
					Во	orrar selección

### Does your paper address subitem 16-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 2 presents detailed intervention outcomes, from both the intention-to-treat (n=513) and per-protocol (n=232) analyses.

<b>16-ii) Primary analysis should be intent-to-treat</b> Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).							
	1	2	3	4	5		
subitem not at all important	0	0	0	0	۲	essential	
					Во	rrar selección	

## Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 2 presents detailed intervention outcomes, from both the intention-to-treat (n=513) and per-protocol (n=232) analyses.

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

## Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the intention-to-treat analysis using the BOCF at T1, an intergroup difference in the primary outcome was found, with a biochemically validated abstinence rate of 26.0% (63/242) in the IG versus 18.8% (51/271) in the CG (odds ratio [OR] 1.50, 95% CI 1.00-2.31; P=.05). After adjusting by CO-oximetry and bupropion intake, no substantial changes were observed (OR 1.52, 95% CI 0.99-2.33; P=.053; pseudo-R2=0.045). In terms of quality of life, no intergroup differences were found at baseline on the VAS (71.8 in the CG versus 69.4 in the IG; P=.07). At 6 months, a significant difference on the EQ-5D-5L VAS was observed between those who had guit and those who had not (73.2 versus 64.7 points, respectively; P=.01) and also between patients in the IG and the CG (71.6 versus 66.7 points, respectively; P=.09), although statistical significance was not reached (P<.05). In terms of variables related to intervention intensity, the mean total interaction time with the patients was 21.2 minutes (SD 18.3; 95% CI 19.0-23.4) in the CG and 121 minutes (SD 157.5; 95% CI 121.1-140.0) in the IG (P<.001), and the mean number of contacts was 2.92 (SD 1.89) in the CG and 45.56 (SD 36.32) in the IG (P<.001). Therefore, the mean interaction duration between the chatbot and patient was 2.65 minutes versus 7.26 minutes between the professional and patient. Contact was defined as the time attending consultation for cessation in the CG or as the chatbot-patient interaction plus the time for performing an activity in the IG, with a pause of more than 90 minutes being considered as the end of a contact.

## 17a-i) Presentation of process outcomes such as metrics of use and intensity of

#### use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).



## Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Patients in the IG who had successfully quit interacted an average time of 176.1 minutes (CI 95% 124.4-227.7) versus 116.6 minutes (95% CI 65.6-167.7) for those who had not (P=.06). In the CG, the mean interaction time was 24.1 minutes (95% CI 19.1-29.2) for patients who had quit smoking versus 23.5 minutes (95% CI 19.8-27.3) for those who had not (P=.84). The average number of contacts in the IG was greater for patients who stopped smoking versus those who did not succeed (59.4 vs 40.9, respectively; P=.004), which was in contrast to the number of contacts in the CG (4.1 versus 3.6, respectively; P=.06).

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

## Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the intention-to-treat analysis using the BOCF at T1, an intergroup difference in the primary outcome was found, with a biochemically validated abstinence rate of 26.0% (63/242) in the IG versus 18.8% (51/271) in the CG (odds ratio [OR] 1.50, 95% CI 1.00-2.31; P=.05). After adjusting by CO-oximetry and bupropion intake, no substantial changes were observed (OR 1.52, 95% CI 0.99-2.33; P=.053; pseudo-R2=0.045).

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

## Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An additional exploratory analysis by subgroups, which the protocol did not contemplate, was performed to assess the intensive use of the chatbot, defined as more than 4 contacts with the chatbot and over 30 minutes of total interaction time throughout the 6 months. The biochemically validated abstinence rate in the IG at T1 was significantly higher for patients who contacted the chatbot intensively versus those who did not (68.6% versus 40.9%, respectively; P=.02), which was in contrast to that observed in the CG (47.6% for patients having intensive contact with the health care worker versus 35.4% who were not; P=.30), for which also intensive contact was defined as more than 4 contacts and over 30 minutes of total interaction time throughout the 6 months.

## 18-i) Subgroup analysis of comparing only users A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii). 1 2 3 4 5 subitem not at all important O O O O O essential

## Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

An additional exploratory analysis by subgroups, which the protocol did not contemplate, was performed to assess the intensive use of the chatbot, defined as more than 4 contacts with the chatbot and over 30 minutes of total interaction time throughout the 6 months. The biochemically validated abstinence rate in the IG at T1 was significantly higher for patients who contacted the chatbot intensively versus those who did not (68.6% versus 40.9%, respectively; P=.02), which was in contrast to that observed in the CG (47.6% for patients having intensive contact with the health care worker versus 35.4% who were not; P=.30), for which also intensive contact was defined as more than 4 contacts and over 30 minutes of total interaction time throughout the 6 months.

**19) All important harms or unintended effects in each group** (for specific guidance see CONSORT for harms)

## Does your paper address CONSORT subitem 19? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No harms or unintended effects were detected

19-i) Include privacy breaches, technical problems Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].							
subitem not at all important		2		4	5 • Bo	essential rrar selección	

### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Telegram operates as a telephone service provider acting as a technological intermediate that does not store the content of the conversation. The chatbot only knows what the users say but there are no metadata in the conversation allowing their identification. No privacy breaches, technical problems or unintended effects were detected during the trial.

## 19-ii) Include qualitative feedback from participants or observations from

### staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.



### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There was a feedback form to the chatbot users when the trial was ended. No technical support service was available during the trial, which the authors believed would improve the chatbot accessibility and the retention rate.


## DISCUSSION

## 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



## Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The aim of this study was to assess the effectiveness of a chatbot, with an evidence-based design and including elements of AI and natural language processing, for helping people stop smoking compared with clinical practice in primary care.

Although no significant difference in smoking cessation rates was obtained, our results suggest an effect that is certainly promising (OR 1.5), with a difference in effect ranging from no effect (OR 1) or a 1% decrease (OR 0.99) in the raw result up to over 2-fold increase (OR 2.33). However, all values within the interval limits are reasonably compatible with the data, given the statistical assumptions made to calculate the interval. Therefore, these results must be interpreted with caution.

22-ii) Highlight unanswered r Highlight unanswered new questions	•		00	futureı	research	1
	1	2	3	4	5	
subitem not at all important	0	0	0	۲	0	essential
					Во	rrar selección

## Does your paper address subitem 22-ii?


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Further evidence is still required to assess the effectiveness of mHealth in smoking cessation. Although there are trials assessing the use of SMS text messages and apps for quitting, interventions using chatbots need to be evaluated, and qualitative studies about cost-effectiveness, usability, and satisfaction must be conducted. Additionally, determining the components that mainly affect effectiveness will be of interest to achieve behavioral changes and increased participation of users, because a strong association appears to exist between the time of use or accomplishment of tasks and dropout rates. From the ethics perspective, the importance of high-quality studies evaluating these treatments must be highlighted, which will prevent the patient from being disfavored by incomplete, biased, or nonevidence-based interventions, and will also avoid decreased accessibility of certain population segments to quality therapies.

## 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

## 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



## Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


The main limitation of this trial was the dropout rate of 54.8% (281/513). Given the pragmatic design of the trial, no further midterm reinforcements or visits could be scheduled. Additionally, 38.8% (94/242) of the IG users never entered the chatbot. Losses to follow-up were homogeneous in both study arms, both quantitatively and in terms of participants' characteristics after the intervention.

## 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

## 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The results are applicable to the smoking population over 18 years of age who goes to their family doctor or primary care nurse in a public health service

# 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting. 1 2 3 4 5 subitem not at all important

## Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our trial has a pragmatic design, with real-life conditions of clinical practice in terms of recruitment (inclusion criteria for patients and professionals), prescribed medication (patients were treated by their assigned practitioners at their usual consultations, without further restrictions), and minimum number of mandatory visits (baseline and at 6 months).

## OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care. (Dej@lo), ClinicalTrials.gov Identifier: NCT03445507

## 24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

https://cuidabot.es/dejalobot

## 25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study has been funded by Instituto de Salud Carlos III through the project "PI17/01942", as part of the Plan Estatal de I+D+I 2013-2016 co-funded by European Regional Development Fund (ERDF) "A way of shaping Europe." The main researcher (EOE) received a grant from the Fundación para la Investigación e Innovación Biomédica en Atención Primaria (FIIBAP) through their 2018 call for grants for promoting research programs.

## X27) Conflicts of Interest (not a CONSORT item)

### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.



### Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

JFA-T, EO-E, and CM-L designed the chatbot and own the intellectual property rights. The remaining research team members (authors, developers, and sponsors) were not involved in the development of the intervention.

## About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *	
O yes, major changes	
O yes, minor changes	
o no	
What were the most important changes you made as a result of using this checklist?	
Tu respuesta	
How much time did you spend on going through the checklist INCLUDING making changes in your manuscript	*
6 h.	
As a result of using this checklist, do you think your manuscript has improved? *	

🔘 yes

이 no

Otro:

Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document
• yes
O no
O Otro:
Borrar selección
Any other comments or questions on CONSORT EHEALTH
Tu respuesta
<b>STOP - Save this form as PDF before you click submit</b> To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.
When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

**Final step: Click submit !** Click submit so we have your answers in our database!

Enviar

## **Borrar formulario**

Nunca envíes contraseñas a través de Formularios de Google.

Este contenido no ha sido creado ni aprobado por Google. <u>Notificar uso inadecuado</u> - <u>Términos del Servicio</u> - <u>Política de Privacidad</u>

## **Google** Formularios